New combo therapy targets rare, aggressive kidney tumors
NCT ID NCT06302569
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two drugs—pembrolizumab (Keytruda) and enfortumab vedotin (Padcev)—in people with rare kidney cancers called collecting duct carcinoma and renal medullary carcinoma. About 23 patients with advanced or metastatic disease will receive the combination for three cycles, then continue pembrolizumab alone. The study aims to see how many patients respond, how long they live without the cancer growing, and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda) and Enfortumab Vedotin (Padcev)
- What this could lead to
- If successful, this could provide a new treatment option for people with rare, aggressive kidney cancers that are hard to treat.
- What could go wrong
- This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BELLINI CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Irccs Istituto Dei Tumori Di Milano
RECRUITINGMilan, 20133, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New combo shows promise for rare kidney cancers
- New drug cocktail targets rare, aggressive kidney cancer
- Immunotherapy combo tested for rare kidney cancer, but trial stopped early
- Scientists launch Largest-Ever study of rare bladder and genital cancers
- New hope for rare cancers: Triple-Drug attack shows promise